Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114119 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Jonathan Noujaim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Maisonneuve-Rosemont Hospital, Montreal, Qc, Canada. Electronic address: jonathan.noujaim.med@ssss.gouv.qc.ca. Hauptthemen laut MEDLINE: Indazoles, Sorafenib, Sulfonamides, Pyrimidines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Desmoid Tumor Research Foundation.
Abstract (Originalsprache)
BACKGROUND: Sorafenib and pazopanib, two tyrosine kinase inhibitors (TKI), are widely used in patients with progressive symptomatic desmoid tumors (DT). Limited real-word data is available on long-term outcomes of patients who progressed on, stopped, or continued TKIs. METHODS: Patients diagnosed with DTs and treated with sorafenib or pazopanib between 2011 and 2022 at 11 institutions were reviewed. Patient history, response to therapy and toxicity were recorded. Statistical analyses utilized Kaplan-Meier and log-rank tests. RESULTS: 142 patients with DT treated with sorafenib (n = 126, 88.7 %) or pazopanib (n = 16, 11.3 %) were analyzed. The median treatment duration was 10.8 months (range: 0.07- 73.9). The overall response rate and the disease control rate were 26.0 % and 95.1 %, respectively. The median tumor shrinkage was - 8.5 % (range -100.0 %- +72.5 %). Among responders, the median time to an objective response was 15.2 months (range: 1.1 to 33.1). The 1-year and 2-year progression-free survival rates were 82 % and 80 %. Dose reductions were necessary in 34 (23.9 %) patients. Grade 3 or higher adverse events were reported in 36 (25.4 %) patients. On the last follow-up, 55 (38.7 %) patients continued treatment. Treatment discontinuation (n = 85, 59.9 %) was mainly for toxicity (n = 35, 45.9 %) or radiological or clinical progression (n = 30, 35.3 %). For the entire cohort, 36 (25.4 %) patients required subsequent treatment. In the 32 responders, only 1 (3.1 %) patient required a subsequent treatment. In patients who discontinued TKI, 25 (44.6 %) with stable disease received subsequent treatment compared to 0 (0.0 %) of responders. CONCLUSION: This retrospective study represents the largest cohort of DT patients treated with sorafenib or pazopanib to date. Discontinuation of treatment in responders is safe. The optimal treatment duration in patients with stable disease remains to be defined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maisonneuve-Rosemont Hospital, Montreal, Qc, Canada. Electronic address: jonathan.noujaim.med@ssss.gouv.qc.ca.
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
- BC Cancer, Victoria, Victoria, BC, Canada.
- McGill University Health Centre, Cedars Cancer Centre, Montreal, Qc, Canada.
- Ottawa Hospital, ON, Canada.
- Centre Hospitalier Universitaire de Québec, Quebec, Qc, Canada.
Förderung
- Desmoid Tumor Research Foundation
Zitieren
APA
Noujaim, J., Gupta, A. A., Holloway, C. L., Saleh, R., Srikanthan, A., Lemieux, C., Soroka, H. P., Tibout, P., Turcotte, R., Feng, X., Abdul Razak, A. R., & Costa, P. (2024). Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114119
Vancouver
Noujaim J, Gupta AA, Holloway CL, Saleh R, Srikanthan A, Lemieux C, et al. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114119
BibTeX
@article{Noujaim2024,
author = {Noujaim, Jonathan and Gupta, Abha A and Holloway, Caroline L and Saleh, Ramy and Srikanthan, Amirrtha and Lemieux, Christopher and Soroka, Hagit Peretz and Tibout, Pauline and Turcotte, Robert and Feng, Xiaolan and Abdul Razak, Albiruni R and Costa, Philippos},
title = {Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114119}
}
EUVIMED